<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611778</url>
  </required_header>
  <id_info>
    <org_study_id>FYB201-C2015-01-P3</org_study_id>
    <nct_id>NCT02611778</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration</brief_title>
  <acronym>COLUMBUS-AMD</acronym>
  <official_title>Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioeq GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioeq GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of the biosimilar&#xD;
      ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular&#xD;
      degeneration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2015</start_date>
  <completion_date type="Actual">June 6, 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The primary endpoint was the absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 2 months (8 weeks) of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 24 Weeks</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 24 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 48 Weeks</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 48 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 12 Months</measure>
    <time_frame>Baseline and 12 Months</time_frame>
    <description>Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 12 months, calculated as the average of the changes from baseline to Week 40, to Week 44 and to Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Absolute change in Foveal Centre Point (FCP) retinal thickness [µm] from baseline to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Absolute change in Foveal Centre Point (FCP) retinal thickness [µm] from baseline to Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Absolute change in Foveal Central Subfield (FCS) retinal thickness [µm] from baseline to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Absolute change in Foveal Central Subfield (FCS) retinal thickness [µm] from baseline to Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Lesion Area From Baseline to Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Absolute change in total lesion area [mm²] from baseline to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Lesion Area From Baseline to Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Absolute change in total lesion area [mm²] from baseline to Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NEI VFQ-25 Composite Score From Baseline to Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Absolute change from baseline to Week 24 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score.&#xD;
The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NEI VFQ-25 Composite Score From Baseline to Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Absolute change from baseline to Week 48 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score.&#xD;
The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active CNV Leakage at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Number and percentage of patients with active CNV leakage at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active CNV Leakage at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Number and percentage of patients with active CNV leakage at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid-free Macula at Each Visit</measure>
    <time_frame>Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48</time_frame>
    <description>Number and percentage of patients with fluid-free macula at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibodies by Scheduled eCRF Visit</measure>
    <time_frame>Baseline and Weeks 1, 4, 12, 24, 48</time_frame>
    <description>Frequency of patients with anti-drug antibodies (ADAs) by scheduled eCRF visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibodies Pre- and Post-first Dosing</measure>
    <time_frame>Baseline and up to Week 48</time_frame>
    <description>Number and percentage of patients with detection of anti-drug antibodies (ADAs) pre-first dosing and post-first dosing (combination of all ADA assessments after first injection of study medication).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">712</enrollment>
  <condition>Age-related Macular Degeneration (AMD)</condition>
  <arm_group>
    <arm_group_label>FYB201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FYB201 is provided as single use vials and will be administered by intra-vitreal injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lucentis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lucentis® is provided as single use vials and will be administered by intra-vitreal injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <arm_group_label>FYB201</arm_group_label>
    <arm_group_label>Lucentis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age ≥ 50 years of either gender&#xD;
&#xD;
          -  Signed informed consent form must be obtained before any study-related procedure is&#xD;
             performed&#xD;
&#xD;
          -  Willingness and ability to undertake all scheduled visits and assessments&#xD;
&#xD;
          -  Women must be postmenopausal or surgically sterile&#xD;
&#xD;
          -  Newly diagnosed, angiographically documented, primary active Choroidal&#xD;
             Neovascularization (CNV) lesion secondary to age-related macular degeneration (AMD)&#xD;
&#xD;
          -  Sufficiently clear ocular media and adequate pupillary dilation to permit good quality&#xD;
             ocular imaging&#xD;
&#xD;
          -  Best-corrected Visual Acuity (BCVA) in the study eye, determined by standardized Early&#xD;
             Treatment Diabetic Retinopathy Study (ETDRS) testing, between 20/32 (0.63) and 20/100&#xD;
             (0.2) Snellen equivalent&#xD;
&#xD;
          -  Foveal Center Point (FCP) retinal thickness in at Screening ≥ 350 µm&#xD;
&#xD;
          -  BCVA in the fellow eye, determined by standardized ETDRS testing, at least 20/100&#xD;
             (0.2) Snellen equivalent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Employees of clinical study sites, individuals directly involved with the conduct of&#xD;
             the study or immediate family members thereof, prisoners, and persons who are legally&#xD;
             institutionalized&#xD;
&#xD;
          -  Any previous treatment with intravitreal (IVT) anti-vascular endothelial growth factor&#xD;
             (VEGF) agent in either eye&#xD;
&#xD;
          -  History of vitrectomy, macular surgery or other surgical intervention for AMD in the&#xD;
             study eye&#xD;
&#xD;
          -  History of IVT or periocular injections of corticosteroids or device implantation&#xD;
             within six months prior to Screening in the study eye&#xD;
&#xD;
          -  Prior treatment with verteporfin (photodynamic therapy), transpupillary thermotherapy,&#xD;
             radiation therapy, or retinal laser treatment (e.g. focal laser photocoagulation) in&#xD;
             the study eye&#xD;
&#xD;
          -  Topical ocular corticosteroids administered for at least 30 consecutive days within&#xD;
             three months prior to Screening&#xD;
&#xD;
          -  Any other intraocular surgery (including cataract surgery) in the study eye within&#xD;
             three months prior to Screening&#xD;
&#xD;
          -  Sub- or intra-retinal hemorrhage that comprises more than 50% of the entire lesion in&#xD;
             the study eye&#xD;
&#xD;
          -  Fibrosis or atrophy involving the center of the fovea or influencing central visual&#xD;
             function in the study eye&#xD;
&#xD;
          -  CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or&#xD;
             pathologic myopia&#xD;
&#xD;
          -  Retinal pigment epithelial tear involving the macula in the study eye&#xD;
&#xD;
          -  History of full-thickness macular hole in the study eye&#xD;
&#xD;
          -  History of retinal detachment in the study eye&#xD;
&#xD;
          -  Current vitreous hemorrhage in the study eye&#xD;
&#xD;
          -  Spherical equivalent of the refractive error in the study eye demonstrating more than&#xD;
             8 diopters of myopia&#xD;
&#xD;
          -  For patients who have undergone prior refractive or cataract surgery in the study eye,&#xD;
             the preoperative refractive error in the study eye cannot exceed 8 diopters of myopia&#xD;
&#xD;
          -  History of corneal transplant in the study eye&#xD;
&#xD;
          -  Aphakia in the study eye. Absence of an intact posterior capsule is allowed if it&#xD;
             occurred as a result of Yttrium-Aluminium-Garnet (YAG) laser posterior capsulotomy in&#xD;
             association with prior posterior chamber intraocular lens (IOL) implantation&#xD;
&#xD;
          -  Active or recent (within 4 weeks) intraocular inflammation of clinical significance in&#xD;
             the study eye such as active infections of the anterior segment (excluding mild&#xD;
             blepharitis) including conjunctivitis, keratitis, scleritis, uveitis or&#xD;
             endophthalmitis&#xD;
&#xD;
          -  Uncontrolled hypertension or glaucoma in the study eye (defined as intraocular&#xD;
             pressure (IOP) ≥30 mm Hg, despite treatment with anti-glaucomatous medication)&#xD;
&#xD;
          -  Ocular disorders in the study eye (i.e. retinal detachment, pre-retinal membrane of&#xD;
             the macula or cataract with significant impact on visual acuity) at the time of&#xD;
             enrollment that may confound interpretation of study results and compromise visual&#xD;
             acuity&#xD;
&#xD;
          -  Any concurrent intraocular condition in the study eye (e.g. glaucoma, cataract or&#xD;
             diabetic retinopathy) that, in the opinion of the Investigator, would either require&#xD;
             surgical intervention during the study to prevent or treat visual loss that might&#xD;
             result from that condition or affect interpretation of study results.&#xD;
&#xD;
          -  Use of other investigational drugs (excluding vitamins, minerals) within 30 days or 5&#xD;
             half-lives from Screening, whichever is longer&#xD;
&#xD;
          -  Any type of advanced, severe or unstable disease, including any medical condition&#xD;
             (controlled or uncontrolled) that could be expected to progress, recur, or change to&#xD;
             such an extent that it may bias the assessment of the clinical status of the patient&#xD;
             to a significant degree or put the patient at special risk&#xD;
&#xD;
          -  Stroke or myocardial infarction within three months prior to Screening&#xD;
&#xD;
          -  Presence of uncontrolled systolic blood pressure &gt; 160 mmHg or uncontrolled diastolic&#xD;
             blood pressure &gt; 100 mmHg&#xD;
&#xD;
          -  Known hypersensitivity to the investigational drug (ranibizumab or any component of&#xD;
             the ranibizumab formulation) or to drugs of similar chemical class or to fluorescein&#xD;
             or any other component of fluorescein formulation&#xD;
&#xD;
          -  Current or planned use of systemic medications known to be toxic to the lens, retina&#xD;
             or optic nerve, including deferoxamine, chloroquine/hydroxychloroquine (Plaquenil®),&#xD;
             tamoxifen, phenothiazines and ethambutol&#xD;
&#xD;
          -  History of recurrent significant infections and/or current treatment for active&#xD;
             systemic infection&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Systemic treatment with high doses of corticosteroids (administration of &gt;10 mg/day of&#xD;
             prednisolone equivalent) during the last six months prior to Screening&#xD;
&#xD;
          -  Inability to comply with study or follow-up procedures&#xD;
&#xD;
          -  Any diagnosis and/or signs of nAMD requiring treatment with an IVT anti-VEGF agent&#xD;
             (e.g. aflibercept, bevacizumab, ranibizumab) within the screening period or at study&#xD;
             treatment initiation (Visit 1) in the fellow eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank G. Holz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bonn, Department of Ophthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zlín</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Bonn, Department of Ophthalmology</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reẖovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnowskie Góry</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bradford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camberley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rugby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <results_first_submitted>September 2, 2021</results_first_submitted>
  <results_first_submitted_qc>September 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 30, 2021</results_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02611778/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02611778/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All 712 patients were screened for eligibility before participating in the active treatment phase of the study, resulting in 722 screenings due to 10 rescreenings. Subjects were not to be entered to trial treatment if any of the eligibility criteria were violated. Of the 712 distinct patients, 477 patients were randomized and treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FYB201</title>
          <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
        </group>
        <group group_id="P2">
          <title>Lucentis</title>
          <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Need for alternative treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set (SAF): The safety set comprised all patients who had received at least one injection with investigational medicinal product.</population>
      <group_list>
        <group group_id="B1">
          <title>FYB201</title>
          <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
        </group>
        <group group_id="B2">
          <title>Lucentis</title>
          <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="238"/>
            <count group_id="B2" value="239"/>
            <count group_id="B3" value="477"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.9" spread="8.26"/>
                    <measurement group_id="B2" value="76.1" spread="7.84"/>
                    <measurement group_id="B3" value="75.5" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="233"/>
                    <measurement group_id="B3" value="469"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks</title>
        <description>The primary endpoint was the absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 2 months (8 weeks) of treatment.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS_US: The FAS_US was based on the intention to treat principle (i.e., patients were analyzed according to their randomized treatment irrespective of the treatment they actually received) and included all patients who received at least one injection of IMP, and for whom BCVA results at least after 1 month were available and who had a screening BCVA between 20/32 and 20/100 Snellen equivalent in the study eye.</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks</title>
          <description>The primary endpoint was the absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 2 months (8 weeks) of treatment.</description>
          <population>FAS_US: The FAS_US was based on the intention to treat principle (i.e., patients were analyzed according to their randomized treatment irrespective of the treatment they actually received) and included all patients who received at least one injection of IMP, and for whom BCVA results at least after 1 month were available and who had a screening BCVA between 20/32 and 20/100 Snellen equivalent in the study eye.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="7.52"/>
                    <measurement group_id="O2" value="5.6" spread="8.63"/>
                    <measurement group_id="O3" value="5.4" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis of biosimilarity of FYB201 and Lucentis was tested with a two-sided equivalence test with an equivalence margin of 3 ETDRS letters. An ANCOVA model was used with the change in BCVA between baseline and Week 8 as the dependent variable, the baseline BCVA as covariate, and the country and the treatment group as fixed effects.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The confidence interval (CI) for treatment difference (FYB201 - Lucentis) was calculated using Least Square Means. If the 90% CI was completely contained in the interval ]-3.5;3.5[ ETDRS letters, equivalence of FYB201 and Lucentis could be concluded.</non_inferiority_desc>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with the change in BCVA between baseline and Week 8 as the dependent variable, the baseline BCVA as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 24 Weeks</title>
        <description>Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 24 weeks of treatment.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 24 Weeks</title>
          <description>Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 24 weeks of treatment.</description>
          <population>FAS_US</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="10.12"/>
                    <measurement group_id="O2" value="7.1" spread="10.42"/>
                    <measurement group_id="O3" value="7.0" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was no formal hypothesis testing.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.96</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with the change in BCVA between baseline and Week 24 as the dependent variable, the baseline BCVA as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 48 Weeks</title>
        <description>Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 48 weeks of treatment.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 48 Weeks</title>
          <description>Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 48 weeks of treatment.</description>
          <population>FAS_US</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="11.67"/>
                    <measurement group_id="O2" value="8.0" spread="11.31"/>
                    <measurement group_id="O3" value="7.9" spread="11.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was no formal hypothesis testing.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.08</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with the change in BCVA between baseline and Week 48 as the dependent variable, the baseline BCVA as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 12 Months</title>
        <description>Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 12 months, calculated as the average of the changes from baseline to Week 40, to Week 44 and to Week 48.</description>
        <time_frame>Baseline and 12 Months</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 12 Months</title>
          <description>Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 12 months, calculated as the average of the changes from baseline to Week 40, to Week 44 and to Week 48.</description>
          <population>FAS_US</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="227"/>
                <count group_id="O3" value="455"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="11.19"/>
                    <measurement group_id="O2" value="7.9" spread="11.01"/>
                    <measurement group_id="O3" value="7.8" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was no formal hypothesis testing.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in least square means</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.04</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with the change in BCVA between baseline and 12 months (average of Weeks 40, 44 and 48) as the dependent variable, the baseline BCVA as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 24</title>
        <description>Absolute change in Foveal Centre Point (FCP) retinal thickness [µm] from baseline to Week 24</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 24</title>
          <description>Absolute change in Foveal Centre Point (FCP) retinal thickness [µm] from baseline to Week 24</description>
          <population>FAS_US</population>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="439"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-203.94" spread="147.104"/>
                    <measurement group_id="O2" value="-205.45" spread="147.199"/>
                    <measurement group_id="O3" value="-204.70" spread="146.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was no formal hypothesis testing.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in least square means</param_type>
            <param_value>0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.469</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.22</ci_lower_limit>
            <ci_upper_limit>19.60</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with the change in FCP retinal thickness between baseline and Week 24 as the dependent variable, the baseline FCP retinal thickness as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 48</title>
        <description>Absolute change in Foveal Centre Point (FCP) retinal thickness [µm] from baseline to Week 48</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 48</title>
          <description>Absolute change in Foveal Centre Point (FCP) retinal thickness [µm] from baseline to Week 48</description>
          <population>FAS_US</population>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="439"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-213.26" spread="161.323"/>
                    <measurement group_id="O2" value="-211.02" spread="151.950"/>
                    <measurement group_id="O3" value="-212.14" spread="156.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was no formal hypothesis testing.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in least square means</param_type>
            <param_value>2.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.632</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.49</ci_lower_limit>
            <ci_upper_limit>21.85</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with the change in FCP retinal thickness between baseline and Week 48 as the dependent variable, the baseline FCP retinal thickness as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 24</title>
        <description>Absolute change in Foveal Central Subfield (FCS) retinal thickness [µm] from baseline to Week 24</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 24</title>
          <description>Absolute change in Foveal Central Subfield (FCS) retinal thickness [µm] from baseline to Week 24</description>
          <population>FAS_US</population>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-180.37" spread="128.522"/>
                    <measurement group_id="O2" value="-181.63" spread="126.466"/>
                    <measurement group_id="O3" value="-181.02" spread="127.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was no formal hypothesis testing.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in least square means</param_type>
            <param_value>-5.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.136</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.62</ci_lower_limit>
            <ci_upper_limit>10.80</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with the change in FCS retinal thickness between baseline and Week 24 as the dependent variable, the baseline FCS retinal thickness as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 48</title>
        <description>Absolute change in Foveal Central Subfield (FCS) retinal thickness [µm] from baseline to Week 48</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 48</title>
          <description>Absolute change in Foveal Central Subfield (FCS) retinal thickness [µm] from baseline to Week 48</description>
          <population>FAS_US</population>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="213"/>
                <count group_id="O3" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-182.85" spread="134.588"/>
                    <measurement group_id="O2" value="-190.75" spread="128.691"/>
                    <measurement group_id="O3" value="-186.86" spread="131.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was no formal hypothesis testing.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in least square means</param_type>
            <param_value>3.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.285</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.28</ci_lower_limit>
            <ci_upper_limit>20.63</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with the change in FCS retinal thickness between baseline and Week 48 as the dependent variable, the baseline FCS retinal thickness as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Lesion Area From Baseline to Week 24</title>
        <description>Absolute change in total lesion area [mm²] from baseline to Week 24</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Lesion Area From Baseline to Week 24</title>
          <description>Absolute change in total lesion area [mm²] from baseline to Week 24</description>
          <population>FAS_US</population>
          <units>mm²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5742" spread="4.79222"/>
                    <measurement group_id="O2" value="-0.7113" spread="5.35854"/>
                    <measurement group_id="O3" value="-0.6418" spread="5.07361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was no formal hypothesis testing.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in least square means</param_type>
            <param_value>0.070</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4709</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.706</ci_lower_limit>
            <ci_upper_limit>0.846</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with the change in total lesion area between baseline and Week 24 as the dependent variable, the baseline total lesion area as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Lesion Area From Baseline to Week 48</title>
        <description>Absolute change in total lesion area [mm²] from baseline to Week 48</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Lesion Area From Baseline to Week 48</title>
          <description>Absolute change in total lesion area [mm²] from baseline to Week 48</description>
          <population>FAS_US</population>
          <units>mm²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6382" spread="4.81194"/>
                    <measurement group_id="O2" value="-1.1814" spread="5.42770"/>
                    <measurement group_id="O3" value="-0.9123" spread="5.13128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was no formal hypothesis testing.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in least square means</param_type>
            <param_value>0.342</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5387</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.547</ci_lower_limit>
            <ci_upper_limit>1.230</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with the change in total lesion area between baseline and Week 48 as the dependent variable, the baseline total lesion area as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NEI VFQ-25 Composite Score From Baseline to Week 24</title>
        <description>Absolute change from baseline to Week 24 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score.&#xD;
The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NEI VFQ-25 Composite Score From Baseline to Week 24</title>
          <description>Absolute change from baseline to Week 24 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score.&#xD;
The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.</description>
          <population>FAS_US</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" spread="9.632"/>
                    <measurement group_id="O2" value="3.55" spread="11.237"/>
                    <measurement group_id="O3" value="3.57" spread="10.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was no formal hypothesis testing.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in least square means</param_type>
            <param_value>0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.886</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with change in NEI VFQ-25 composite score between baseline and Week 24 as dependent variable, baseline NEI VFQ-25 composite score as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NEI VFQ-25 Composite Score From Baseline to Week 48</title>
        <description>Absolute change from baseline to Week 48 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score.&#xD;
The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NEI VFQ-25 Composite Score From Baseline to Week 48</title>
          <description>Absolute change from baseline to Week 48 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score.&#xD;
The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.</description>
          <population>FAS_US</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" spread="12.205"/>
                    <measurement group_id="O2" value="3.75" spread="13.190"/>
                    <measurement group_id="O3" value="4.53" spread="12.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was no formal hypothesis testing.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in least square means</param_type>
            <param_value>1.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.027</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>3.42</ci_upper_limit>
            <estimate_desc>An ANCOVA model was used for the analysis with change in NEI VFQ-25 composite score between baseline and Week 48 as dependent variable, baseline NEI VFQ-25 composite score as covariate, and (pooled) country and treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active CNV Leakage at Week 24</title>
        <description>Number and percentage of patients with active CNV leakage at Week 24</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Active CNV Leakage at Week 24</title>
          <description>Number and percentage of patients with active CNV leakage at Week 24</description>
          <population>FAS_US</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>CNV leakage</title>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="226"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No CNV leakage</title>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active CNV Leakage at Week 48</title>
        <description>Number and percentage of patients with active CNV leakage at Week 48</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Active CNV Leakage at Week 48</title>
          <description>Number and percentage of patients with active CNV leakage at Week 48</description>
          <population>FAS_US</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>CNV leakage</title>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="234"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No CNV leakage</title>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluid-free Macula at Each Visit</title>
        <description>Number and percentage of patients with fluid-free macula at each visit</description>
        <time_frame>Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48</time_frame>
        <population>FAS_US</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid-free Macula at Each Visit</title>
          <description>Number and percentage of patients with fluid-free macula at each visit</description>
          <population>FAS_US</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="236"/>
                    <count group_id="O3" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                    <measurement group_id="O2" value="234"/>
                    <measurement group_id="O3" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="226"/>
                    <count group_id="O3" value="456"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="230"/>
                    <count group_id="O3" value="453"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="168"/>
                    <measurement group_id="O3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="458"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="236"/>
                    <count group_id="O3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="234"/>
                    <count group_id="O3" value="460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="137"/>
                    <measurement group_id="O3" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="458"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="445"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="222"/>
                    <count group_id="O2" value="221"/>
                    <count group_id="O3" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="187"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="218"/>
                    <count group_id="O3" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="182"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="217"/>
                    <count group_id="O3" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="189"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="220"/>
                    <count group_id="O3" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="221"/>
                    <count group_id="O3" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="213"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No fluid-free macula</title>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-drug Antibodies by Scheduled eCRF Visit</title>
        <description>Frequency of patients with anti-drug antibodies (ADAs) by scheduled eCRF visit</description>
        <time_frame>Baseline and Weeks 1, 4, 12, 24, 48</time_frame>
        <population>SAF</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-drug Antibodies by Scheduled eCRF Visit</title>
          <description>Frequency of patients with anti-drug antibodies (ADAs) by scheduled eCRF visit</description>
          <population>SAF</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Positive anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="234"/>
                    <measurement group_id="O2" value="233"/>
                    <measurement group_id="O3" value="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Positive anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="228"/>
                    <count group_id="O3" value="454"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Positive anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="226"/>
                    <measurement group_id="O3" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="226"/>
                    <count group_id="O3" value="452"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Positive anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="224"/>
                    <measurement group_id="O3" value="449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="225"/>
                    <count group_id="O3" value="450"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Positive anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="219"/>
                    <measurement group_id="O3" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="225"/>
                    <count group_id="O3" value="454"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Positive anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="213"/>
                    <measurement group_id="O3" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-drug Antibodies Pre- and Post-first Dosing</title>
        <description>Number and percentage of patients with detection of anti-drug antibodies (ADAs) pre-first dosing and post-first dosing (combination of all ADA assessments after first injection of study medication).</description>
        <time_frame>Baseline and up to Week 48</time_frame>
        <population>SAF</population>
        <group_list>
          <group group_id="O1">
            <title>FYB201</title>
            <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O2">
            <title>Lucentis</title>
            <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-drug Antibodies Pre- and Post-first Dosing</title>
          <description>Number and percentage of patients with detection of anti-drug antibodies (ADAs) pre-first dosing and post-first dosing (combination of all ADA assessments after first injection of study medication).</description>
          <population>SAF</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-first dosing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="236"/>
                    <count group_id="O3" value="468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Positive anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="231"/>
                    <measurement group_id="O3" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-first dosing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="475"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Positive anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative anti-drug antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="224"/>
                    <measurement group_id="O3" value="447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first treatment up to Week 48</time_frame>
      <desc>All Adverse Events are reported in this record from First Patient First Treatment until Last Patient Last Visit. SAF</desc>
      <group_list>
        <group group_id="E1">
          <title>FYB201</title>
          <description>Patients received FYB201 at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
        </group>
        <group group_id="E2">
          <title>Lucentis</title>
          <description>Patients received Lucentis (ranibizumab) at a dose of 0.5mg (0.05mL of a 10mg/mL solution) as twelve monthly intravitreal injections</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hydroureter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Choroidal neovascularisation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="238"/>
                <counts group_id="E2" events="30" subjects_affected="19" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" events="25" subjects_affected="12" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Retinal pigment epithelial tear</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="238"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="11" subjects_at_risk="238"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Visual acuity tests abnormal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" events="25" subjects_affected="14" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Development</name_or_title>
      <organization>bioeq GmbH</organization>
      <phone>+498024463330</phone>
      <email>columbus@bioeq.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

